Dr Lal PathLabs’ board has approved a bonus issue of 1:1, a dividend of ₹7 per share, and a new employee stock option plan (RSU 2025). The decisions were made at the board meeting on October 31, 2025. The company will issue bonus shares from its securities premium account and seek shareholder approval for the RSU 2025 plan, while expanding its authorized share capital to ₹200 crore.
Key Financial Decisions
During a meeting held on October 31, 2025, the Board of Directors at Dr Lal PathLabs approved several key financial actions:
- A second interim dividend of ₹7 per equity share (at 70% on a face value of ₹10) for the financial year 2025-26, with a record date set for November 7, 2025.
- A bonus issue of equity shares in the proportion of 1:1 (one bonus share for every one held), subject to statutory and regulatory approvals.
The bonus shares will be issued to members holding shares as of the record date.
Employee Stock Option Plan
The Board approved the introduction of the “Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025” (RSU 2025). The options and shares reserved under this plan will be allocated from the existing “Dr. Lal PathLabs Employee Stock Option Plan 2022” (ESOP 2022), and are subject to member approval. The maximum number of options granted under the RSU 2025 will be 5,27,403.
Capital Restructuring
The Board also approved increasing the authorized share capital from ₹1,07,96,00,000 to ₹2,00,00,00,000. The amended clause V of MOA will reflect this change, dividing the capital into 20,00,00,000 equity shares of ₹10 each. The Amended MOA will be submitted for approval by the Members of the Company.
Subsidiary Update
Suburban Diagnostics (India) Private Limited, a subsidiary company, will voluntarily liquidate on February 11, 2025, with the business undertaking transferred to the Parent Company.
Dr. Lal PathLabs Kenya Private Limited was dissolved during the year ended March 31, 2025.
Source: BSE
